A comparison of different protease inhibitors on coronary heart disease risk.
Coleman
Craig I
CI
University of Connecticut, School of Pharmacy, Storrs, USA.
White
C Michael
CM
D023241:Antiretroviral Therapy, Highly Active; D000069446:Atazanavir Sulfate; D002986:Clinical Trials as Topic; D003327:Coronary Disease / Q000139:chemically induced*; D017320:HIV Protease Inhibitors / Q000008:administration & dosage / Q000009:adverse effects*; D006679:HIV Seropositivity / Q000150:complications; D006801:Humans; D006949:Hyperlipidemias / Q000139:chemically induced*; D019888:Nelfinavir / Q000008:administration & dosage / Q000009:adverse effects*; D009842:Oligopeptides / Q000008:administration & dosage / Q000009:adverse effects*; D011725:Pyridines / Q000008:administration & dosage / Q000009:adverse effects*; D012307:Risk Factors
D017320:HIV Protease Inhibitors; D009842:Oligopeptides; D011725:Pyridines; D000069446:Atazanavir Sulfate; D019888:Nelfinavir